Back to results
US 12,259,390 B2Granted
Cancer antigen targets and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichel Sadelain, Fabiana Perna
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.
Claims13
A method for identifying a target tumor surface antigen comprising:
- i) identifying a plurality of cell-surface expressed proteins in a tumor sample from a proteomics database, a transcriptomics database, surface proteomics analysis of the tumor sample, and flow cytometric analysis of the tumor sample, wherein each protein of said plurality has a redundant expression in at least 2 databases;
- and
- ii) identifying the target tumor surface antigen from said plurality of cell-surface expressed proteins wherein said target tumor surface antigen has:
- a) an expression level in the tumor sample higher than its expression level in a normal sample of the type of tissue from which the tumor is derived;
- and
- b) an expression level in a normal tissue sample that is no more than one standard deviation above the normal peak of the protein expression level distribution of a plurality of samples of normal tissues, other than the tissue from which the tumor sample is derived.
3 more elements
Dependencies are inferred from the claim text.